FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a treatment for advanced melanoma that had shown promise in clinical trials. RP1 (vusolimogene oderparepvec) is an oncolytic immunotherapy given in combination with nivolumab (Opdivo). RP1 + nivolumab would have been a second-line treatment for patients with advanced melanoma that did ... Read More
